Qiagen Files U.S. GAAP Quarterly Report for First Quarter 2026

Qiagen ( (QGEN) ) has shared an update.

Qiagen N.V. has filed a Form 6-K reporting that, for the quarter ended March 31, 2026, it prepared its financial statements under U.S. GAAP, furnishing a detailed quarterly report covering condensed consolidated financials, operating and financial review, market risk disclosures and risk factors. The filing, signed by Chief Financial Officer Roland Sackers on May 7, 2026, underscores the company’s continued adherence to U.S. reporting standards for foreign private issuers and provides investors with updated visibility on its balance sheet, cash position, debt levels and broader risk profile at the start of 2026.

The most recent analyst rating on (QGEN) stock is a Hold with a $38.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.

Spark’s Take on QGEN Stock

According to Spark, TipRanks’ AI Analyst, QGEN is a Neutral.

The score is supported primarily by improved 2025 profitability and solid operating/free cash flow with manageable leverage, plus constructive 2026 guidance. These positives are tempered by very weak technicals (price far below key moving averages and bearish MACD) and some fundamental consistency risks (historical earnings/FCF volatility and near-term headwinds impacting early 2026).

To see Spark’s full report on QGEN stock, click here.

More about Qiagen

Qiagen N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies used in molecular diagnostics, applied testing, pharma and academic research. Its products enable the extraction, purification and analysis of DNA, RNA and proteins, serving laboratories, healthcare providers and research institutions worldwide.

Average Trading Volume: 1,973,844

Technical Sentiment Signal: Sell

Current Market Cap: $6.91B

See more data about QGEN stock on TipRanks’ Stock Analysis page.